The Acute Effect of Mango Intake (Mangifera Indica L.) on Blood Pressure and Blood Glucose
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04057495 |
Recruitment Status :
Completed
First Posted : August 15, 2019
Last Update Posted : July 23, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Blood Pressure | Other: further fasting Other: white bread consumption Other: mango consumption | Not Applicable |
Cardiovascular disease (CVD) is the leading cause of mortality in the U.S, and aging is the largest risk factor for vascular diseases. Both male and female adults have increased risk for CVD as they age. For postmenopausal women, this risk is particularly elevated due to the loss of the protective effect of estrogen. It is evident that nutrition plays a crucial role in prevention of chronic diseases such as heart disease, stroke and cancer. Scientific evidence shows that high intake of plant-based food lowers the risk of CVD and many other chronic diseases.
Polyphenolic compounds in fruits and nuts have been the focus of extensive research regarding their potential to reduce risk for a number of chronic diseases. However, fruits and nuts vary largely in the type and amounts of phytonutrients they provide. Mango (Mangifera Idica L.), a commonly cultivated fruit worldwide, is rich in polyphenolic compounds such as gallic acid, mangiferin, quercetin glycosides, ferulic acid, and hydroxybenzoic acid. Many of those bioactive compounds have been found to have anti-diabetic and anti-inflammatory effects in cell models. For instance, mangiferin has been proved to effectively reducing glucose-induced endoplasmic reticulum stress by inhibiting IREα phosphorylation and ROS production in endothelial cells. However, it is unknown if the phytonutrients in mango will demonstrate a similar impact in humans. Therefore, the overall objective of this study is to investigate the effects of acute mango intake on blood pressure and blood glucose.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 6 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | The Acute Effect of Mango Intake (Mangifera Indica L.) on Blood Pressure and Blood Glucose |
Actual Study Start Date : | November 11, 2019 |
Actual Primary Completion Date : | March 1, 2020 |
Actual Study Completion Date : | April 1, 2020 |
Arm | Intervention/treatment |
---|---|
Placebo Comparator: no mango intake
No mango consumption on the study visit
|
Other: further fasting
2 hours of fasting |
Experimental: white bread with same amount of calorie as mango
White bread consumption on the study visit
|
Other: white bread consumption
113 grams of white bread consumption |
Experimental: mango consumption
mango consumption on the study visit
|
Other: mango consumption
330 grams of mango consumption |
- Change in blood pressure [ Time Frame: Baseline, 2 hours ]Changes in measures of blood pressure (mmHg) from baseline to two hours following fasting or consumption of white bread or mango.
- Change in blood glucose [ Time Frame: Baseline, 2 hours ]Changes in blood glucose from baseline to two hours following fasting or consumption of white bread or mango.
- Change in insulin levels [ Time Frame: Baseline, 2 hours ]Changes in insulin from baseline to two hours following fasting or consumption of white bread or mango.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Postmenopausal female: 50-70 years
- Women: lack of menses for at least one year and FSH 23-116.3 mlU/mL
- Subject is willing and able to comply with the study protocols.
- Subject is willing participate in all study procedures
- BMI 25.0 - 40 kg/m2
- Weight ≥ 110 pounds
Exclusion Criteria:
- BMI ≥ 40 kg/m2
- Dislike or allergy for mango
- Self-reported use of daily anticoagulation agents including aspirin, NSAIDs
- Vegan, Vegetarians, food faddists or those consuming a non-traditional diet
- Alcohol consumption > 3 drinks/week (i.e. 1 bottle of beer, 1 glass of wine, and 1 shot of hard liquor)
- Fruit consumption ≥ 2 cups/day
- Vegetable consumption ≥ 3 cups/day for females
- Fatty Fish ≥ 3 times/week
- Coffee/tea ≥ 3 cups/day
- Dark chocolate ≥ 3 oz/day
- Self-reported restriction of physical activity due to a chronic health condition
- Self-reported chronic/routine high intensity exercise
- Self-reported diabetes
- Blood pressure ≥ 140/90 mm Hg
- Self-reported renal or liver disease
- Self-reported heart disease, which includes cardiovascular events and Stroke
- Abnormal Liver, CBC or Chemistry panels (laboratory values outside the reference range) if determined to be clinically significant by the study physician.
- Self-reported cancer within past 5 years
- Self-reported malabsorption

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04057495
United States, California | |
Regal Human Nutrition Research Center | |
Davis, California, United States, 95616 |
Responsible Party: | University of California, Davis |
ClinicalTrials.gov Identifier: | NCT04057495 |
Other Study ID Numbers: |
1453713 |
First Posted: | August 15, 2019 Key Record Dates |
Last Update Posted: | July 23, 2021 |
Last Verified: | July 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Blood glucose Insulin |